Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs News

Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs Aktie VALOR 942236 / ISIN ARDEUT110236

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

01.06.26	Aktien von Microsoft, Amazon, Apple & Co.: Das hat sich in Q1 2026 im Depot von Jeremy Grantham getan (finanzen.ch) Auch im ersten Quartal 2026 kam es im Aktienportfolio von Jeremy Granthams Investmentgesellschaft Grantham, Mayo & van Otterloo (GMO) zu einigen Veränderungen.» mehr
05.03.26	Bridgewater-Portfolio Q4 2025: Diese Aktien kaufte der von Ray Dalio gegründete Fonds (finanzen.ch) Im 4. Quartal 2025 gab es viel Bewegung im Portfolio von Bridgewater Associates: Keine der zehn grössten Aktienbeteiligungen des von Ray Dalio gegründeten Hedgefonds blieb unverändert.» mehr
02.03.26	Commerzbank-Portfolio: Auf diese Aktien setzt die Bank in Q4 2025 (finanzen.ch) Im vierten Quartal 2025 hat die Commerzbank einige Änderungen an ihren US-Beteiligungen vorgenommen. Diese Aktien schafften es im Depot nun unter die Top Ten.» mehr
26.02.26	Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer (EN, Johnson & Johnson)
26.02.26	Johnson & Johnson Completes Catheter Portfolio with Launch of CEREGLIDE™ 42, CEREGLIDE™ 57, and INNERGLIDE™ 7 (EN, Johnson & Johnson)
24.02.26	Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA) (EN, Johnson & Johnson)
23.02.26	Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer (EN, Johnson & Johnson)
21.02.26	TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years (EN, Johnson & Johnson)
19.02.26	RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer (EN, Johnson & Johnson)
18.02.26	Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania (EN, Johnson & Johnson)
18.02.26	Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania (EN, Johnson & Johnson)
18.02.26	RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer (EN, Johnson & Johnson)
17.02.26	FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month (EN, Johnson & Johnson)
07.02.26	Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium (EN, Johnson & Johnson)
03.02.26	Johnson & Johnson Releases Report on Surgeon Burnout as More than 40% Surveyed Consider Leaving the Profession (EN, Johnson & Johnson)
03.02.26	Johnson & Johnson Highlights New Scientific Evidence and Reinforces its Leadership with Portfolio Advancements at AF Symposium (EN, Johnson & Johnson)
27.01.26	DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible (EN, Johnson & Johnson)
27.01.26	Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile (EN, Johnson & Johnson)
21.01.26	Johnson & Johnson reports Q4 and Full-Year 2025 results (EN, Johnson & Johnson)
16.01.26	New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder (EN, Johnson & Johnson)
15.01.26	Johnson & Johnson Introduces Mobile Simulator App to Support Breast Augmentation Patients (EN, Johnson & Johnson)
13.01.26	Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting (EN, Johnson & Johnson)
10.01.26	RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer (EN, Johnson & Johnson)
09.01.26	Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments (EN, Johnson & Johnson)
08.01.26	Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award (EN, Johnson & Johnson)
08.01.26	Dividendensatz vs. Dividendenrendite: Unterschiede und Bedeutung für Investoren (finanzen.ch) Viele Anleger investieren ihr Geld gerne in Dividenden-Aktien, um sich so passives Einkommen aufzubauen. Durch die Zahlungen von regelmässigen Dividenden ergibt sich für den Investor ein kalkulierbarer Ertragsstrom. Doch wie wählt man die Dividendenaktien am besten aus und was ist der Unterschied zwischen dem Dividendensatz und der Dividendenrendite?» mehr
07.01.26	Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (EN, Johnson & Johnson)
06.01.26	Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study (EN, Johnson & Johnson)
29.12.25	Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies (EN, Johnson & Johnson)
22.12.25	European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor (EN, Johnson & Johnson)
19.12.25	Johnson & Johnson Backs HRS Registry to Advance Real-World Evidence in PFA (EN, Johnson & Johnson)
18.12.25	Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma (EN, Johnson & Johnson)
13.12.25	U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* (EN, Johnson & Johnson)
06.12.25	Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma (EN, Johnson & Johnson)
05.12.25	Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC (EN, Johnson & Johnson)
03.12.25	Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40 (EN, Johnson & Johnson)
17.11.25	New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis (EN, Johnson & Johnson)
17.11.25	Johnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics (EN, Johnson & Johnson)
10.11.25	L.A. Lakers coach JJ Redick lists his Brooklyn ‘trophy’ penthouse for $6.2 million (MarketWatch)
06.11.25	DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma (EN, Johnson & Johnson)
06.11.25	FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder (EN, Johnson & Johnson)
04.11.25	Johnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research (EN, Johnson & Johnson)
04.11.25	Johnson & Johnson One Year Data Demonstrate Durable Performance and Safety of the Shockwave Javelin Peripheral IVL Catheter in Late-Breaking Presentation at VIVA 2025 (EN, Johnson & Johnson)
03.11.25	Johnson & Johnson Confirms Durability of IVL in Complex, Below-the-Knee Anatomy in Late-Breaking Presentation at VIVA 2025 (EN, Johnson & Johnson)
03.11.25	Johnson & Johnson Showcases Latest Advancements in Pulsed Field Ablation with Multiple Clinical and Real-world Studies at APHRS and JPHRS (EN, Johnson & Johnson)
31.10.25	Johnson & Johnson submits application to U.S. FDA for STELARA® (ustekinumab) in the treatment of pediatric ulcerative colitis (EN, Johnson & Johnson)
29.10.25	Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting (EN, Johnson & Johnson)
28.10.25	Johnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare (EN, Johnson & Johnson)
27.10.25	New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile (EN, Johnson & Johnson)
27.10.25	Johnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare (EN, Johnson & Johnson)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	53.12	2.00 %	K V
Novartis	117.98	1.85 %	K V
Swiss Re	118.15	1.68 %	K V
Kuehne+Nagel Int	191.85	1.40 %	K V
Givaudan	2’869.00	1.06 %	K V
Swisscom	649.00	-0.61 %	K V
Lonza Grp	485.60	-1.18 %	K V
Holcim	74.44	-1.19 %	K V
ABB	83.10	-1.84 %	K V
Logitech Intl	91.48	-2.35 %	K V